<?xml version='1.0' encoding='utf-8'?>
<document id="22829999"><sentence text="TB and HIV Therapeutics: Pharmacology Research Priorities." /><sentence text="An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis" /><sentence text=" Among patients with tuberculosis, co-infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard of care" /><sentence text=" To ensure that combinations of anti-tuberculosis drugs and antiretrovirals are safe and are tested at doses most likely to be effective, selected pharmacokinetic studies based on knowledge of their metabolic pathways and their capacity to induce or inhibit metabolizing enzymes of companion drugs must be conducted" /><sentence text=" Drug interaction studies should be followed up by evaluations in larger populations to evaluate safety and pharmacodynamics more fully" /><sentence text=" Involving patients with HIV in trials of TB drugs early in development enhances the knowledge gained from the trials and will ensure that promising new tuberculosis treatments are available to patients with HIV as early as possible" /><sentence text=" In this review, we summarize current and planned pharmacokinetic and drug interaction studies involving investigational and licensed tuberculosis drugs and antiretrovirals and suggest priorities for tuberculosis-HIV pharmacokinetic, pharmacodynamic, and drug-drug interaction studies for the future" /><sentence text=" Priority studies for children and pregnant women with HIV and tuberculosis co-infection are briefly discussed" /><sentence text="" /></document>